50
Participants
Start Date
August 7, 2019
Primary Completion Date
September 21, 2021
Study Completion Date
October 21, 2021
SB12 (proposed eculizumab biosimilar)
600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
Soliris (eculizumab)
600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
Municipal Institution Cherkasy Regional Oncology Dispensary of Cherkasy Regional Council, Cherkasy
Vinnytsia Regional Clinical Hospital n.a. M.I.Pyrohov, Vinnytsia
Fortis Memorial Research Institute, Gurgaon
Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh
Apollo Hospitals International Limited, Chennai
Amrita Institute of Medical Sciences and Research Centre, Kochi
Nil Ratan Sircar Medical College and Hospital, Kolkata
Hospital Ampang, Ampang
Hospital Sultanah Aminah, Johor Bahru
Queen Elizabeth Hospital - Kota Kinabalu, Kota Kinabalu
Hospital Tengku Ampuan Afzan, Kuantan
Hospital Pulau Pinang, Pulau Pinang
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Tlalpan
Colentina Clinical Hospital, Bucharest
Emergency University Hospital, Bucharest
Prof Dr I Chiricuta Institute of Oncology, Cluj-Napoca
Filantropia Municipal Clinical Hospital, Craiova
Samsung Medical Center, Seoul
Seoul National University Hospital, Seoul
National Cheng Kung University Hospital, Tainan City
National Taiwan University Hospital, Taipei
Tri-Service General Hospital, Taipei
Chang Gung Memorial Hospital, Taoyuan District
Chulalongkorn University, Bangkok
Srinagarind Hospital, Nai Muang
Communal Non-profit Enterprise Regional Center of Oncology, Kharkiv
Poltava Regional Clinical Hospital n.a. M.V. Sklifosovskyi, Poltava
Samsung Bioepis Co., Ltd.
INDUSTRY